Format

Send to

Choose Destination
Handb Exp Pharmacol. 2017;236:101-131. doi: 10.1007/164_2016_45.

Key Questions for Translation of FFA Receptors: From Pharmacology to Medicines.

Author information

1
MedImmune, LLC, Gaithersburg, MD, 20878, USA.
2
Epigen Biosciences, 10225 Barnes Canyon Rd, San Diego, CA, 92121, USA. cjenkinson@epigenbiosciences.com.

Abstract

The identification of fatty acids as ligands for the G-protein coupled free fatty acid (FFA) receptor family over 10 years ago led to intensive chemistry efforts to find small-molecule ligands for this class of receptors. Identification of potent, selective modulators of the FFA receptors and their utility in medicine has proven challenging, in part due to their complex pharmacology. Nevertheless, ligands have been identified that are sufficient for exploring the therapeutic potential of this class of receptors in rodents and, in the case of FFA1, FFA2, FFA4, and GPR84, also in humans. Expression profiling, the phenotyping of FFA receptor knockout mice, and the results of studies exploring the effects of these ligands in rodents have uncovered a number of indications where engagement of one or a combination of FFA receptors might provide some clinical benefit in areas including diabetes, inflammatory bowel syndrome, Alzheimer's, pain, and cancer. In this chapter, we will review the clinical potential of modulating FFA receptors based on preclinical and in some cases clinical studies with synthetic ligands. In particular, key aspects and challenges associated with small-molecule ligand identification and FFA receptor pharmacology will be addressed with a view of the hurdles that need to be overcome to fully understand the potential of the receptors as therapeutic targets.

KEYWORDS:

Diabetes; FFA; GPR120; GPR40; GPR41; GPR43; IBD

PMID:
27873087
DOI:
10.1007/164_2016_45
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center